The antimicrobial properties of gold were first described by Robert Koch back in 1890, when he reported on the activity of potassium dicyanidoaurate(I) against Mycobacterium tuberculosis. More recent reports on the antimicrobial properties of gold complexes have been summarized in several review articles. The FDA-approved oral antirheumatic gold(I) drug Auranofin exhibits excellent antibacterial properties in vitro and in vivo. Compounds Au1 and Au2 were originally part of a series of gold(I) phosphine thiolate complexes synthesized to investigate their biological properties. The original synthesis of Au2 was described by The two compounds stand out with their high activity against the two fungal strains as well as MRSA in the initial CO-ADD screening, where 6 other analogues were also tested (Au-S1-S6, Figure in the SI). Even though there are only a few atoms of difference between the compounds, the activity profile changes drastically (Table in SI). This implies that it is not just the metal nor the ligand alone that is responsible for the observed activity. For example, combining 2-sulfanylpyrimidine with a trifuran-2-yl-phosphane ligand gave complex Au1 which had high activity against both MRSA and the fungal strains. In contrast, the compound with the same 2-sulfanylpyrimidine ligand on the triphenylphosphine gold complex (Au-S4, Figure in SI) showed no activity against any of the tested strains. Conversely, the triphenylphosphine gold complex with a 2-sulfanylpyridine ligand (Au2) had high activity against MRSA and the fungal strains, but the same thiolate ligand with the trifuran-2-ylphosphane gold complex (Au-S1) possessed only moderate activity. Interestingly, the introduction of a trifluoromethyl group on the thiolate ligand seemed to increase specificity towards bacteria, as no antifungal activity was observed for these compounds (Au-S3